文献速递胸部肿瘤

帕博利珠单抗联合或不联合仑伐替尼一线治疗PD-L1肿瘤比例评分≥1%的转移性非小细胞肺癌(LEAP-007):一项随机、双盲、3期试验

Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.
PubMed 文献 · J Thorac Oncol · 2023-12-29

LEAP-007研究纳入623例未经治疗、PD-L1肿瘤比例评分≥1%且无EGFR/ROS1/ALK变异的IV期非小细胞肺癌患者,随机接受仑伐替尼+帕博利珠单抗或安慰剂+帕博利珠单抗。中位随访15.9个月,中位OS分别为14.1个月与16.4个月(HR=1.10),中位PFS分别为6.6个月与4.2个月(HR=0.78)。因无效性标准达到及毒性差异,研究揭盲并停止仑伐替尼/安慰剂。

要点

  • 仑伐替尼+帕博利珠单抗较安慰剂+帕博利珠单抗未显示有利的获益-风险特征。
  • 中位OS:仑伐替尼组14.1个月 vs 安慰剂组16.4个月(HR=1.10)。
  • 3-5级治疗相关不良事件发生率:仑伐替尼组57.9% vs 安慰剂组24.4%。

核心结论

  • 仑伐替尼联合帕博利珠单抗相比安慰剂联合帕博利珠单抗未显示出有利的获益-风险特征。
  • 帕博利珠单抗单药仍是许多地区获批的PD-L1肿瘤比例评分≥1%且无EGFR/ALK变异的转移性NSCLC一线治疗选择。

研究设计与样本

  • LEAP-007(NCT03829332/NCT04676412)是一项随机、双盲、3期试验。
  • 纳入既往未经治疗、IV期NSCLC、PD-L1肿瘤比例评分≥1%、无EGFR/ROS1/ALK可靶向变异的患者,按1:1随机分组。

主要发现

  • 共623例患者随机分组。
  • 中位随访15.9个月,中位OS:仑伐替尼+帕博利珠单抗组14.1个月(95%CI 11.4‒19.0)vs 安慰剂+帕博利珠单抗组16.4个月(95%CI 12.6‒20.6),HR=1.10(95%CI 0.87‒1.39),p=0.79744(满足无效性标准)。
  • 中位PFS:仑伐替尼+帕博利珠单抗组6.6个月(95%CI 6.1‒8.2)vs 安慰剂+帕博利珠单抗组4.2个月(95%CI 4.1‒6.2),HR=0.78(95%CI 0.64‒0.95)。
  • 3-5级治疗相关不良事件:仑伐替尼+帕博利珠单抗组57.9%(309例中179例)vs 安慰剂+帕博利珠单抗组24.4%(312例中76例)。

关键数值与推荐

  • 仑伐替尼20 mg或安慰剂每日一次口服;所有患者接受帕博利珠单抗200 mg每3周一次,最多35个周期。
  • 主要终点为根据RECIST 1.1评估的PFS和OS;OS无效性分析在第四次独立数据与安全监查委员会审查时进行,无效性界值为单侧p<0.4960。
  • 数据与安全监查委员会建议揭盲并停止仑伐替尼和安慰剂。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lenvatinib plus pembrolizumab was found to have antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic NSCLC in the LEAP-007 study (NCT03829332/NCT04676412). METHODS: Patients with previously untreated stage IV NSCLC with programmed cell death-ligand 1 tumor proportion score of at least 1% without targetable EGFR/ROS1/ALK aberrations were randomized 1:1 to lenvatinib 20 mg or placebo once daily; all patients received pembrolizumab 200 mg every 3 weeks for up to 35 cycles. Primary end points were progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival (OS). We report results from a prespecified nonbinding futility analysis of OS performed at the fourth independent data and safety monitoring committee review (futility bound: one-sided p < 0.4960). RESULTS: A total of 623 patients were randomized. At median follow-up of 15.9 months, median (95% confidence interval [CI]) OS was 14.1 (11.4‒19.0) months in the lenvatinib plus pembrolizumab group versus 16.4 (12.6‒20.6) months in the placebo plus pembrolizumab group (hazard ratio = 1.10 [95% CI: 0.87‒1.39], p = 0.79744 [futility criterion met]). Median (95% CI) PFS was 6.6 (6.1‒8.2) months versus 4.2 (4.1‒6.2) months, respectively (hazard ratio = 0.78 [95% CI: 0.64‒0.95]). Grade 3 to 5 treatment-related adverse events occurred in 57.9% of patients (179 of 309) versus 24.4% (76 of 312). Per data and safety monitoring committee recommendation, the study was unblinded and lenvatinib and placebo were discontinued. CONCLUSIONS: Lenvatinib plus pembrolizumab did not have a favorable benefit‒risk profile versus placebo plus pembrolizumab. Pembrolizumab monotherapy remains an approved treatment option in many regions for first-line metastatic NSCLC with programmed cell death-ligand 1 tumor proportion score of at least 1% without EGFR/ALK alterations.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Yang JC, Han B, De La Mora Jiménez E, et al. Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial. J Thorac Oncol. 2023. PMID: 38159809. doi:10.1016/j.jtho.2023.12.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。